Survival outcomes with first-line VEGF-targeted therapies in metastatic renal cell carcinoma: real-world evidence from a single center
Aims: Fifty percent of patients with metastatic renal cell carcinoma (RCC) die within the first year. Therefore, survival in the first-line setting is of paramount importance. Cabozantinib has been introduced for use in the first-line setting. We plan to conduct a study on its contribution to survival in Turkiye's popu...